Form 4: Tarsus Pharmaceuticals Director Exercises Stock Options, Reports Beneficial Ownership
SEC Form 4 Filing
Director Andrew D. Goldberg exercised stock options in Tarsus Pharmaceuticals, increasing his beneficial ownership.
Summary
- On March 7, 2025, Andrew D. Goldberg, a director of Tarsus Pharmaceuticals, exercised stock options to acquire 7,000 shares of common stock at a price of $12.89 per share.
- Following the transaction, Goldberg directly owns 13,350 shares of Tarsus Pharmaceuticals common stock.
- The stock options were granted in connection with Goldberg's service as a non-employee director and vested in full on the one-year anniversary of the grant date.
- The options were originally granted on June 15, 2021, and expire on June 15, 2032.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings of company stock.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects an insider's confidence in the company, but the number of shares involved is relatively small.
Key Dates
| Date | Description |
|---|---|
| 06/15/2021 | Date of original option grant |
| 03/07/2025 | Date of transaction (option exercise) |
| 03/11/2025 | Date of report signature |
| 06/15/2032 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.